244 related articles for article (PubMed ID: 27571742)
1. Preferred Physical Characteristics of Vaginal Film Microbicides for HIV Prevention in Pittsburgh Women.
Fan MD; Kramzer LF; Hillier SL; Chang JC; Meyn LA; Rohan LC
Arch Sex Behav; 2017 May; 46(4):1111-1119. PubMed ID: 27571742
[TBL] [Abstract][Full Text] [Related]
2. Optimizing HIV prevention for women: a review of evidence from microbicide studies and considerations for gender-sensitive microbicide introduction.
Doggett EG; Lanham M; Wilcher R; Gafos M; Karim QA; Heise L
J Int AIDS Soc; 2015; 18(1):20536. PubMed ID: 26700845
[TBL] [Abstract][Full Text] [Related]
3. Intravaginal practices and microbicide acceptability in Papua New Guinea: implications for HIV prevention in a moderate-prevalence setting.
Vallely A; Fitzgerald L; Fiya V; Aeno H; Kelly A; Sauk J; Kupul M; Neo J; Millan J; Siba P; Kaldor JM
BMC Res Notes; 2012 Nov; 5():613. PubMed ID: 23116431
[TBL] [Abstract][Full Text] [Related]
4. Acceptability of vaginal film, soft-gel capsule, and tablet as potential microbicide delivery methods among African women.
Nel AM; Mitchnick LB; Risha P; Muungo LT; Norick PM
J Womens Health (Larchmt); 2011 Aug; 20(8):1207-14. PubMed ID: 21774672
[TBL] [Abstract][Full Text] [Related]
5. Educating men about vaginal microbicides: considerations from Kenya.
Gitome SW; Kwena ZA; Harper CC; Cohen CR; Bukusi EA
Cult Health Sex; 2020 Jun; 22(6):660-674. PubMed ID: 31241426
[TBL] [Abstract][Full Text] [Related]
6. Perspectives from Young South African and Zimbabwean Women on Attributes of Four (Placebo) Vaginal Microbicide Delivery Forms.
Weinrib R; Browne EN; Shapley-Quinn MK; van der Straten A; Beksinska M; Mgodi N; Musara P; Mphili N; Schwartz JL; Ju S; Hanif H; Montgomery ET;
AIDS Behav; 2020 Feb; 24(2):637-647. PubMed ID: 31254190
[TBL] [Abstract][Full Text] [Related]
7. The acceptability of an investigational vaginal microbicide, PRO 2000 Gel, among women in a phase I clinical trial.
Morrow K; Rosen R; Richter L; Emans A; Forbes A; Day J; Morar N; Maslankowski L; Profy AT; Kelly C; Abdool Karim SS; Mayer KH
J Womens Health (Larchmt); 2003 Sep; 12(7):655-66. PubMed ID: 14583106
[TBL] [Abstract][Full Text] [Related]
8. Acceptability and preferences for vaginal dosage forms intended for prevention of HIV or HIV and pregnancy.
Woodsong C; Holt JD
Adv Drug Deliv Rev; 2015 Sep; 92():146-54. PubMed ID: 25703190
[TBL] [Abstract][Full Text] [Related]
9. Microbicide preference among young women in California.
Holt BY; Morwitz VG; Ngo L; Harrison PF; Whaley KJ; Pettifor A; Nguyen AH
J Womens Health (Larchmt); 2006 Apr; 15(3):281-94. PubMed ID: 16620187
[TBL] [Abstract][Full Text] [Related]
10. Stated product formulation preferences for HIV pre-exposure prophylaxis among women in the VOICE-D (MTN-003D) study.
Luecke EH; Cheng H; Woeber K; Nakyanzi T; Mudekunye-Mahaka IC; van der Straten A;
J Int AIDS Soc; 2016; 19(1):20875. PubMed ID: 27247202
[TBL] [Abstract][Full Text] [Related]
11. Acceptability of Carraguard vaginal microbicide gel among HIV-infected women in Chiang Rai, Thailand.
Whitehead SJ; McLean C; Chaikummao S; Braunstein S; Utaivoravit W; van de Wijgert JH; Mock PA; Siraprapasiri T; Friedland BA; Kilmarx PH; Markowitz LE
PLoS One; 2011; 6(9):e14831. PubMed ID: 21915249
[TBL] [Abstract][Full Text] [Related]
12. Acceptability and performance of a nonwoven device for vaginal drug delivery among women and their male partners in KwaZulu-Natal, South Africa.
Hart CW; Joanis C; Hartmann M; Milford C; Smit J; Beksinska M; Rambally-Greener L; Pienaar J; Mabude Z; Butterworth GAM; Sokal D; Jenkins D
Eur J Contracept Reprod Health Care; 2019 Oct; 24(5):390-398. PubMed ID: 31517545
[No Abstract] [Full Text] [Related]
13. An assessment of the likely acceptability of vaginal microbicides for HIV prevention among women in rural Ghana.
Abdulai MA; Baiden F; Adjei G; Afari-Asiedu S; Adjei K; Tawiah C; Newton S
BMC Womens Health; 2012 Nov; 12():40. PubMed ID: 23114222
[TBL] [Abstract][Full Text] [Related]
14. Design aspects of vaginal applicators that influence acceptance among target users.
Bakke AJ; Zaveri T; Higgins MJ; Ziegler GR; Hayes JE
Sci Rep; 2021 May; 11(1):9802. PubMed ID: 33963262
[TBL] [Abstract][Full Text] [Related]
15. Preferences and practices related to vaginal lubrication: implications for microbicide acceptability and clinical testing.
Braunstein S; van de Wijgert J
J Womens Health (Larchmt); 2005 Jun; 14(5):424-33. PubMed ID: 15989415
[TBL] [Abstract][Full Text] [Related]
16. Male Partner Influence on Women's HIV Prevention Trial Participation and Use of Pre-exposure Prophylaxis: the Importance of "Understanding".
Montgomery ET; van der Straten A; Stadler J; Hartmann M; Magazi B; Mathebula F; Laborde N; Soto-Torres L
AIDS Behav; 2015 May; 19(5):784-93. PubMed ID: 25416076
[TBL] [Abstract][Full Text] [Related]
17. Acceptability of PRO2000 vaginal gel among HIV un-infected women in Pune, India.
Joglekar N; Joshi S; Kakde M; Fang G; Cianciola M; Reynolds S; Mehendale S;
AIDS Care; 2007 Jul; 19(6):817-21. PubMed ID: 17573603
[TBL] [Abstract][Full Text] [Related]
18. Acceptability of and Adherence to an Antiretroviral-Based Vaginal Microbicide among Pregnant Women in the United States.
Montgomery ET; Noguchi LM; Dai JY; Pan J; Biggio J; Hendrix C; Isaacs K; Watts DH; Schwartz JL; Piper J; Beigi R
AIDS Behav; 2018 Feb; 22(2):402-411. PubMed ID: 28550377
[TBL] [Abstract][Full Text] [Related]
19. Vaginal film for prevention of HIV: using visual and tactile evaluations among potential users to inform product design.
Guthrie KM; Rohan L; Rosen RK; Vargas SE; Shaw JG; Katz D; Kojic EM; Ham AS; Friend D; Buckheit KW; Buckheit RW
Pharm Dev Technol; 2018 Mar; 23(3):311-314. PubMed ID: 28592183
[TBL] [Abstract][Full Text] [Related]
20. Women's interest in vaginal microbicides.
Darroch JE; Frost JJ
Fam Plann Perspect; 1999; 31(1):16-23. PubMed ID: 10029928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
